Adenosine A2A receptor antagonists as novel anti-Parkinsonian agents: a review of structure-activity relationships.
The adenosine A2A receptor (AA2AR) has emerged as an attractive target for the treatment of Parkinson's disease. Evidence suggests that antagonists of the AA2AR may be neuroprotective and may help to alleviate the symptoms of Parkinson's disease. During last decade, many efforts have been accomplished searching potent and selective AA2AR antagonists. In this field, various xanthines and non-xanthine heterocyclic compounds of monocyclic, bicyclic and tricyclic nucleus possessing very good affinity with a broad range of selectivity have been proposed. The aim of this article is to summarize available data on different chemical classes of AA2AR antagonists including those in clinical development, and briefly present an overview of the structure-activity relationships found for these compounds.
Azam
F
F
Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Seventh of October University, Misurata, Libya. faizulazam@gmail.com
Ibn-Rajab
I A
IA
Alruiad
A A
AA
D058917:Adenosine A2 Receptor Antagonists; D000818:Animals; D000978:Antiparkinson Agents / Q000737:chemistry* / Q000494:pharmacology* / Q000627:therapeutic use; D006571:Heterocyclic Compounds / Q000138:chemical synthesis / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D010300:Parkinson Disease / Q000188:drug therapy*; D013329:Structure-Activity Relationship; D014970:Xanthines / Q000138:chemical synthesis / Q000494:pharmacology / Q000627:therapeutic use
D058917:Adenosine A2 Receptor Antagonists; D000978:Antiparkinson Agents; D006571:Heterocyclic Compounds; D014970:Xanthines